MustGrow Biologics stock analysis
MustGrow Biologics (0C0) Stock Price & Analysis
0C0 Stock Chart & Stats
- Day’s Range
- EUR 0.22 - EUR 0.23
- 52-Week Range
- EUR 0.16 - EUR 0.58
- Previous Close
- EUR 0.22
- Volume
- N/A
- Average Volume (3M)
- 300
- Market Cap
- EUR 18.00M
- Enterprise Value
- EUR 20.73M
- Total Cash (Recent Filing)
- EUR 4.37M
- Total Debt (Recent Filing)
- EUR 515.57K
- Price to Earnings (P/E)
- ―
- Beta
- 0.51
- Next Earnings
- Dec 01, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Modest debt relative to equity reduces near-term balance-sheet pressure and leaves more financial flexibility than a highly leveraged structure. This can help the company fund regulatory and commercialization work while limiting interest-related strain during periods of weak operating performance.
Gross Margin
A gross margin of roughly 53% indicates that the company’s products or technology can retain meaningful value after direct costs. If revenue scale improves, this margin profile could provide operating leverage, although current overhead and development spending still prevent profitability.
Asset-Light Commercialization Model
An intellectual-property commercialization model can scale more efficiently than building a large direct-to-farm distribution operation. Licensing and royalty arrangements may allow established agriculture companies to handle manufacturing, registration, and sales while MustGrow focuses on technology and regulatory progress.
Bears Say
Revenue Contraction
Sharp revenue contraction undermines confidence in near-term commercial traction and makes the business more dependent on future product launches, approvals, or partner execution. Sustained volatility also reduces operating leverage because fixed development and corporate costs are spread over a smaller revenue base.
Persistent Unprofitability
Large operating and net losses show that current business scale is insufficient to cover the company’s cost structure. Continued losses can consume equity, constrain investment in regulatory and commercial programs, and increase the need for financing before the business reaches sustainable earnings.
Negative Cash Generation
Ongoing negative operating and free cash flow means the company is consuming rather than generating cash from its activities. If this persists, MustGrow may have less flexibility to fund research, approvals, and commercialization internally, increasing reliance on external capital or partner support.
MustGrow Biologics News
0C0 FAQ
What was MustGrow Biologics’s price range in the past 12 months?
What is MustGrow Biologics’s market cap?
When is MustGrow Biologics’s upcoming earnings report date?
How were MustGrow Biologics’s earnings last quarter?
Is MustGrow Biologics overvalued?
Does MustGrow Biologics pay dividends?
What is MustGrow Biologics’s EPS estimate?
How many shares outstanding does MustGrow Biologics have?
What happened to MustGrow Biologics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of MustGrow Biologics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
MustGrow Biologics
MustGrow Biologics Corp. is an agricultural biotechnology enterprise specializing in the creation and commercialization of natural crop protection solutions. These offerings, including biopesticides, biofumigants, and bioherbicides, are uniquely derived from mustard seed. The company provides a pre-planting soil biofumigation technique aimed at combating soil-borne diseases and pests across diverse agricultural commodities, such as fruits and vegetables. Furthermore, MustGrow is actively developing a bioherbicide to manage undesirable plant growth, intended for use in organic farming, home gardens, and broader agricultural sectors. Their portfolio also extends to post-harvest food preservation, applying treatments to inhibit sprouting, disease, and pathogens, thereby enhancing the shelf life of stored products. A significant offering is CannaPM, an active compound effective against both fungal soil ailments and foliar diseases. Established in 2014 and headquartered in Saskatoon, Canada, the company adopted the name MustGrow Biologics Corp. in March 2018, having previously operated as Duport Capital Ltd.
- Sector
- Basicmaterials
- Industry
- Agricultural Inputs
- CEO
- Corey J. Giasson
- Employees
- 8
- Website
- www.mustgrow.ca
- Address
- 201 1st Avenue South, Saskatoon, SK, S7K 1J5, CA
MustGrow Biologics (0C0) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 6 | 9 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 4 | 0 | 8 |
